Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evommune, Inc. Common Stock (NY:EVMN)

11.88 +0.35 (+3.04%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evommune, Inc. Common Stock

Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
From Evommune, Inc.
Via Business Wire
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? ↗
Via Stocktwits
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
News headline image
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
From Evommune, Inc.
Via Business Wire
News headline image
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade ↗
Evommune has two autoimmune disorder treatments with blockbuster potential. 
Via The Motley Fool
News headline image
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Evommune Announces $125 Million Private Placement
From Evommune, Inc.
Via Business Wire
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
From Evommune, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.